Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Affymax Company Profile - Aug 23, 2011

VIEWS: 20 PAGES: 9

Affymax, Inc. is a biopharmaceutical company developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, Hematide (peginesatide), is designed to treat anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent (ESA) designed to stimulate production of red blood cells. The Company completed treatment and follow up of patients with anemia associated with chronic renal failure in the Phase III clinical program for Hematide. Its Phase III clinical program included four open-label, randomized controlled clinical trials. The two trials, called EMERALD 1 and EMERALD 2, were conducted in dialysis patients and designed to evaluate the safety and efficacy of Hematide and its ability to maintain hemoglobin levels in a corrected range.

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Affymax, Inc.
                                                                                         440 Wheelers Farms Road
                                                                                         Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:CBNN                                  Key Data

   Affymax, Inc. is a biopharmaceutical company developing drugs to improve the              Ticker:
   treatment of serious and often life-threatening conditions. Its product candidate,        AFFY
   Hematide (peginesatide), is designed to treat anemia associated with chronic renal
   failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent (ESA)     2010 Sales:
   designed to stimulate production of red blood cells. The Company completed
                                                                                             112,521,000
   treatment and follow up of patients with anemia associated with chronic renal failure
   in the Phase III clinical program for Hematide. Its Phase III clinical program included
   four open-label, randomized controlled clinical trials. The two trials, called EMERALD    Major Industry:
   1 and EMERALD 2, were conducted in dialysis patients and designed to evaluate the         Drugs, Cosmetics & Health
   safety and efficacy of Hematide and its ability to maintain hemoglobin levels in a        Care
   corrected range.
                         Stock Chart                                   Officers              Sub Industry:
                                                                      Chairman               Ethical Drug Manufacturers
                                                                  Hollings C. Renton
                                                                                             Country:
                                                               Chief Executive Officer       United States
                                                                    John A. Orwin
                                                                                             Currency:
                                                               Chief Financial Officer       U.S. Dollars
                                                                  Herbert C. Cross
                                                                                             Fiscal Year Ends:
                                                                                             December

                                                                                             Employees
                                                                                             140

                                                                                             Exchanges:
                                                                                             NAS

                                                                                             Share Type:
               Stock Price (8/12/2011): 4.51
                                                                                             Common
                 Recent stock performance
                    1 Week      -13.1%
                    4 Weeks     -39.3%                                                       Market Capitalization:
                    13 Weeks    -35.4%                                                       159,130,010
                    52 Weeks    -32.8%
                                                                
								
To top